Clinical Trial Update: Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) [Phase 2]

View source ↗

Summary

Phase 2 FIGHT-202 trial updates show efficacy and safety data for pemigatinib in advanced/metastatic or surgically unresectable cholangiocarcinoma after prior t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-23